Aimmune Therapeutics (NASDAQ:AIMT) was downgraded by research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research report issued on Tuesday.
Several other equities analysts also recently issued reports on AIMT. Credit Suisse Group set a $47.00 price objective on shares of Aimmune Therapeutics and gave the company a “buy” rating in a report on Thursday, May 10th. ValuEngine raised shares of Aimmune Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 22nd. Wedbush reissued an “outperform” rating and issued a $72.00 price target on shares of Aimmune Therapeutics in a research note on Wednesday, May 30th. Zacks Investment Research raised shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $34.00 price target on the stock in a research note on Friday, May 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $64.00 price target on shares of Aimmune Therapeutics in a research note on Monday, March 5th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $53.67.
Aimmune Therapeutics stock opened at $30.77 on Tuesday. The firm has a market capitalization of $1.77 billion, a PE ratio of -11.79 and a beta of -0.34. Aimmune Therapeutics has a fifty-two week low of $16.25 and a fifty-two week high of $42.00.
In other news, CFO Eric Bjerkholt acquired 1,600 shares of the business’s stock in a transaction that occurred on Wednesday, June 13th. The stock was purchased at an average cost of $30.41 per share, for a total transaction of $48,656.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Douglas T. Sheehy sold 3,296 shares of the firm’s stock in a transaction dated Tuesday, May 22nd. The stock was sold at an average price of $33.00, for a total transaction of $108,768.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 364,493 shares of company stock worth $11,580,119. Insiders own 14.70% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. First Republic Investment Management Inc. acquired a new stake in Aimmune Therapeutics during the fourth quarter worth about $202,000. Virtu Financial LLC acquired a new stake in Aimmune Therapeutics during the fourth quarter worth about $239,000. Xact Kapitalforvaltning AB acquired a new stake in Aimmune Therapeutics during the first quarter worth about $207,000. Teacher Retirement System of Texas acquired a new stake in Aimmune Therapeutics during the fourth quarter worth about $282,000. Finally, WINTON GROUP Ltd acquired a new stake in Aimmune Therapeutics during the first quarter worth about $262,000. Hedge funds and other institutional investors own 79.49% of the company’s stock.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.